1.
Clin Case Rep
; 9(4): 1933-1936, 2021 Apr.
Artículo
en Inglés
| MEDLINE
| ID: mdl-33936618
RESUMEN
CPX-351, a promising new agent for patients with treatment-related and secondary acute myeloid leukemia can lead to a severe whole-body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.